EGFR and non-small cell lung carcinoma: The hypothesis to use EGFR-TKI in the adjuvant setting has been investigated in the last 20 years, even if the first results from the SWOG S0023 trial [172] and BR16 study [173] in which either unresectable stage III patients or IB-IIIA NSCLC patients received adjuvant gefitinib compared to placebo, did not show any improvement in OS or disease-free survival.